| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.15B | 2.07B | 2.67B | 3.01B | 2.57B | 2.43B |
| Gross Profit | 823.14M | 869.50M | 758.95M | 1.27B | 1.17B | 1.09B |
| EBITDA | 444.80M | 328.58M | 400.64M | 840.11M | 908.34M | 852.15M |
| Net Income | 254.69M | 244.52M | 191.93M | 551.10M | 627.57M | 563.98M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 5.54B | 5.45B | 5.53B | 4.98B | 4.04B |
| Cash, Cash Equivalents and Short-Term Investments | 1.51B | 1.51B | 230.80M | 604.87M | 1.12B | 512.00M |
| Total Debt | 0.00 | 246.90M | 427.39M | 640.15M | 360.20M | 62.26M |
| Total Liabilities | -5.01B | 532.81M | 688.34M | 959.98M | 808.06M | 498.92M |
| Stockholders Equity | 5.01B | 5.01B | 4.76B | 4.57B | 4.17B | 3.54B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 309.45M | -308.77M | -334.54M | 241.36M | 331.71M |
| Operating Cash Flow | 0.00 | 405.17M | 119.64M | 127.43M | 742.22M | 650.30M |
| Investing Cash Flow | 0.00 | -189.15M | -245.58M | -163.41M | -925.48M | -1.52B |
| Financing Cash Flow | 0.00 | -215.42M | -247.73M | 120.41M | 298.18M | 1.11B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ₹9.82B | 17.66 | ― | 0.52% | 28.67% | 50.12% | |
66 Neutral | ₹1.88B | 34.22 | ― | 1.11% | -37.34% | -45.55% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | ₹5.61B | 697.51 | ― | ― | 15.56% | 2114.71% | |
59 Neutral | ₹1.46B | 87.13 | ― | 0.37% | 42.23% | -50.43% | |
57 Neutral | ₹5.81B | 36.57 | ― | ― | 2.76% | 30.68% | |
56 Neutral | ₹9.39B | -20.11 | ― | 0.56% | 16.82% | ― |
Chemcon Speciality Chemicals has announced that its trading window for dealing in company securities will be closed for designated persons and their immediate relatives from January 1, 2026, until 48 hours after the release of its unaudited financial results for the quarter and nine months ended December 31, 2025, in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s internal code of conduct. The company has indicated that the date of the board meeting to consider and approve these unaudited results will be communicated separately, signaling the upcoming earnings disclosure period and reinforcing its compliance framework for insider trading safeguards.